Best US Biotech Stocks to Invest In
AI-curated Biotech stock ideas for the US market, each with a buy signal, future-value target and a short thesis. Refreshed every weekday from end-of-day data.
20 picks · prices as of close 2026-07-28
Jazz Pharmaceuticals plc
Undervalued specialty biotech with improving sentiment, earnings resilience, and multiple late-stage growth drivers.
▸Ranked top biotech by Zen Ratings; limited current pricing data here.
Intellia Therapeutics, Inc.
CRISPR leader with meaningful pipeline optionality and high-reward catalyst potential over the next year.
▸Morningstar lists it among most undervalued biotech names.
CRISPR Therapeutics AG
Strong gene-editing platform, liquid shares, and durable investor interest support upside from clinical catalysts.
▸Morningstar flags it as one of the most undervalued biotech stocks.
BioMarin Pharmaceutical Inc.
Profitable rare-disease biotech with steadier fundamentals and room for rerating on execution.
▸Morningstar includes it among undervalued biotech stocks.
Royalty Pharma plc
Cash-generating biotech royalty model offers defensive growth and catalyst-backed upside.
▸Morningstar highlights it as undervalued relative to covered biotech peers.
Vertex Pharmaceuticals Incorporated
Category leader with exceptional profitability, strong momentum, and expanding pipeline optionality.
▸Persistent momentum and strong institutional sponsorship support the name.
Regeneron Pharmaceuticals, Inc.
High-quality biotech with durable earnings, large-cap liquidity, and multiple near-term readout catalysts.
▸Analyst confidence and catalyst-rich pipeline underpin current support.
Amgen Inc.
Large-cap biotech with defensive cash flow, visible growth, and share-repurchase support.
▸Institutional ownership and steady fundamentals favor accumulation.
Alnylam Pharmaceuticals, Inc.
RNAi leader with accelerating commercial traction and strong multi-product upside.
▸Positive momentum and expanding product adoption drive the setup.
Exact Sciences Corporation
Liquid diagnostics-biotech hybrid with turnaround potential and major test-launch catalysts.
▸Near-term commercial catalysts and improving sentiment support recovery.
Incyte Corporation
Cash-rich biotech with valuation support and pipeline catalysts after a reset.
▸Valuation appeal and upcoming data readouts drive interest.
Gilead Sciences, Inc.
Large, liquid biotech offering income, earnings stability, and pipeline-driven rerating potential.
▸Strong cash generation and analyst support keep shares investable.
Moderna, Inc.
High-optional biotech with vaccine/platform leverage and event-driven upside from pipeline milestones.
▸Pipeline catalysts exist, but momentum remains uneven.
Biogen Inc.
Deep-value biotech with improving execution and optional upside from pipeline advances.
▸Valuation support and product-cycle improvement are the key setup.
Zoetis Inc.
Defensive animal-health biotech with consistent growth, liquidity, and lower execution risk.
▸Steady fundamentals and institutional demand support the stock.
AbbVie Inc.
Not pure biotech, but liquid healthcare innovator with strong cash flow and pipeline renewal.
▸Analyst support and earnings durability favor a buy-the-dip stance.
Illumina, Inc.
Sequencing leader with turnaround potential if growth reaccelerates and sentiment improves.
▸Catalyst-sensitive setup, but operating momentum is still rebuilding.
Neurocrine Biosciences, Inc.
Profitable biotech with strong commercial execution and pipeline-driven upside.
▸Strong momentum and healthy fundamentals support current buying.
Revvity, Inc.
Life-science tools/diagnostics platform with attractive liquidity and cyclical recovery potential.
▸Institutional interest and improving sector sentiment provide support.
Summit Therapeutics Inc.
High-beta clinical biotech with major readout-driven upside and strong speculative momentum.
▸Powerful catalyst profile, but risk remains elevated ahead of data.